SURPASS-II

Primary research question: Is tirzepatide noninferior and superior to semaglutide in patients with type 2 diabetes?

Study design: Open-label, 40-week, phase 3 trial

Population

Number of patients studied: 1879
Inclusion criteria: Patients with type 2 diabetes
Exclusion criteria: Not specified

Interventions

Experimental group: Tirzepatide (5 mg, 10 mg, or 15 mg)
Control group: Semaglutide (1 mg)

Primary outcome: Change in glycated hemoglobin level from baseline to 40 weeks

Secondary outcomes

Reductions in body weight: least-squares mean estimated treatment difference (Tirzepatide vs Semaglutide): −1.9 kg (5 mg), −3.6 kg (10 mg), and −5.5 kg (15 mg) (P<0.001 for all comparisons)

Hypoglycemia (blood glucose level, <54 mg per deciliter): 0.6% (5 mg), 0.2% (10 mg), 1.7% (15 mg) in tirzepatide; 0.4% in semaglutide

Changes in lipid levels: triglyceride and serum very-low-density lipoprotein levels were lower and high-density lipoprotein cholesterol levels were higher in patients receiving tirzepatide than in those receiving semaglutide

Conclusion

In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks.